A Study to Assess Safety and Efficacy of CHO-H01 as a Single Agent/Combined With Lenalidomide in Subjects With Refractory or Relapsed Non-Hodgkin's Lymphoma

Eligibility Criteria

• * Life expectancy of \>12 weeks.
• * Body mass index of 18 to 32 kg/m2.
• * Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2.
• * Phase I: Have histologically (laboratory test) confirmed CD20 + non-Hodgkin's lymphoma according to the World Health Organization's 2016 classification:
• 1. Low grade lymphoma: follicular lymphoma (Grades 1-3a), marginal zone lymphoma, small lymphocytic lymphoma;
• 2. Other lymphoma: DLBCL (NOS: to include germinal center B-cell-like \[GCB\] and activated B-cell-like \[ABC\]), follicular lymphoma Grade 3b, mantle cell lymphoma; primary mediastinal large B-cell lymphoma.
• * Phase IIa: Histologically confirmed CD20 + non-Hodgkin's lymphoma according to the World Health Organization's 2016 classification, only low grade lymphoma: follicular lymphoma (Grades 1-3a), marginal zone lymphoma, small lymphocytic lymphoma.
• * Have at least one measurable lesion that is at least 1.5 cm in its largest dimension.
• * Off treatment for 30 days from last anti-CD20 infusion until planned administration of CHO-H01.
• * If no original sample is available, is willing and able to provide an adequate tumor biopsy sample at Screening.
• * Have adequate cardiac function: without clinically significant and/or uncontrolled heart disease.
• * Must be sterile, or have a monogamous partner who is surgically sterile, or at least 2 years postmenopausal, or be committed to use an acceptable form of birth control for the duration of the study (male), and for the duration of the study and for 3 months following the last CHO-H01 administration (female).
• * Must not have a history of egg allergy or allergic reactions to any component of CHO-H01.
• * Must not have any known or current illnesses (such as autoimmune disease, unless well controlled or resolved), infection, or other condition that could limit study compliance or interfere with assessments.
• * Subjects who have received anti-programmed death-ligand 1 (PD-L1), programmed cell death 1 (PD-1), or cytotoxic T-lymphocyte associated protein 4 (CTLA-4) therapy.
• * Subjects who have completed an autologous stem cell transplant within 100 days prior to CHO-H01 therapy or an allogeneic stem cell transplant.
• * Subjects with known hepatitis B surface antigen (HBsAg) seropositive or known or suspected active hepatitis C infection with detectable viral load.
• * Subjects with known human immunodeficiency virus (HIV) infection
• * Subjects who have had radiation therapy, major surgical procedure or live vaccinations within 28 days prior to CHO-H01 administration.
• * Subjects with a history of type I hypersensitivity or anaphylactic reactions to murine proteins or to previous infusions of CD20 monoclonal antibodies.
• * Subjects who have received (or are receiving) systemic corticosteroids:
• 1. At a daily dose higher than 15 mg prednisone or equivalent within 14 days prior to the first administration of CHO-H01;
• 2. Topical, inhaled, nasal, and ophthalmic steroids are allowed.
• * Inadequate bone marrow, hepatic or renal function.
• * Subjects with a history of seizure disorder.
• * Subjects who are pregnant or breast feeding.
• * Subjects with any contraindications to lenalidomide (Only for phase IIa).